Objective: The aim of the study was to evaluate the durability of efficacy of the Integrated Care (IC) program in a Swedish context. The IC program is a person-centered flexible assertive community treatment approach delivered through a novel mechanism: a resource group clinical microsystem for each patient.
Methods: All patients with schizophrenia in a Gothenburg urban-sector catchment area were randomly assigned to either the IC or the Rational Rehabilitation (RR) programs. Sixty-six patients were interviewed and assessed by independent interviewers before treatment, after treatment (24 months), and at follow-up (five years). Analysis was by intention to treat.
Results: At the five-year follow-up, significant improvements were noted in social functioning and consumer satisfaction in the IC group (N=35) compared with the RR group (N=31). No patients were lost to services in either program.
Conclusions: The major finding was the durability of efficacy of the IC program.
Download full-text PDF |
Source |
---|---|
http://dx.doi.org/10.1176/appi.ps.201300164 | DOI Listing |
Clin J Gastroenterol
January 2025
Division of Gastroenterology and Hepatology, Saitama Children's Medical Center, 1-2 Shintoshin, Chuo-ku, Saitama, 3308777, Japan.
Eosinophilic gastrointestinal disorders (EGIDs) are treated with corticosteroids and food allergen elimination. However, treatment for refractory cases is not standardized. We demonstrate the efficacy of vedolizumab, an anti-α4β7 integrin agent, in 2 children with duodenal ulcers developed by non-eosinophilic esophagitis EGIDs.
View Article and Find Full Text PDFTransl Lung Cancer Res
December 2024
Department of Medical Oncology, Fudan University Shanghai Cancer Center, Shanghai, China.
Background: The combination therapy of the B-Raf proto-oncogene (BRAF) inhibitor dabrafenib and the mitogen-activated protein kinase kinase (MEK) inhibitor Trametinib has shown favorable outcomes in patients initially identified with BRAF mutations. However, there are currently no large-scale study data focusing on the use of a triple therapy regimen of epidermal growth factor receptor tyrosine kinase inhibitor (EGFR-TKI) plus dabrafenib and trametinib in patients with newly concomitant BRAF mutations after acquiring resistance to EGFR-TKIs. Our study aimed to explore the efficacy and safety of the triple therapy regimen through a multi-center real-world experience.
View Article and Find Full Text PDFFront Immunol
January 2025
RNAimmune, Inc., Germantown, MD, United States.
Background: The unrelenting emergence of SARS-CoV-2 variants has significantly challenged the efficacy of existing COVID-19 vaccines. Enhancing the stability and immunogenicity of the spike protein is critical for improving vaccine performance and addressing variant-driven immune evasion.
Methods: We developed an mRNA-based vaccine, RV-1730, encoding the Delta variant spike protein with the S6P mutation to enhance stability and immunogenicity.
Photodiagnosis Photodyn Ther
January 2025
Department of Prosthetic Dental Sciences, College of Dentistry. King Saud University. Riyadh, Saudi Arabia PO Box-60169. Electronic address:
Aim: To investigate the effectiveness of unconventional post space disinfection techniques, specifically Er:YAG laser, Temoporfin, and Carbon Nanoparticles (CNPs), in improving Martens hardness (MH), eliminating the smear layer (SL), and enhancing the push-out bond strength (PBS) of glass fiber posts in canal dentin.
Methods: An in vitro study was conducted utilizing 80 single-rooted extracted human teeth, which were decoronated and subjected to standardized root canal preparation. The teeth were equally distributed into four experimental groups: Group 1 (NaOCl + EDTA), Group 2 (Er: YAG laser + EDTA), Group 3 (Temoporfin + EDTA), and Group 4 (CNPs + EDTA).
Lung Cancer
January 2025
Department of Medical Oncology, Princess Alexandra Hospital, Woolloongabba, Queensland 4102, Australia; The School of Biomedical Sciences, Institute of Health and Biomedical Innovation, Queensland University of Technology, Brisbane, Queensland 4059, Australia; Translational Research Institute, Woolloongabba, Queensland 4102, Australia. Electronic address:
The enhanced comprehension of the molecular pathways underpinning oncogenesis in non-small cell lung cancer (NSCLC) has led to the advancement of personalized treatment for individuals with actionable mutations using targeted therapies. The rearranged during transfection (RET) proto-oncogene, is critical in the embryonic development of various tissues, including renal, neural, and neuroendocrine tissue. RET fusions have been observed in approximately 1-2% of NSCLC cases.
View Article and Find Full Text PDFEnter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!